Events

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit  2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. Announces Clinical Data on NMS-03592088 selected for Oral Presentation at AACR Annual Meeting 2023

Nerviano Medical Sciences S.r.l. Announces Clinical Data on NMS-03592088 selected for Oral Presentation at AACR Annual Meeting 2023

NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the  Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia  will be reported in an oral presentation by Dr. Antonio Curti, MD, PhD,  IRCCS Azienda Ospedaliero-Universitaria di Bologna, at the upcoming AACR Annual Meeting which will be held April 14 – 19, Orange County Convention Center, Orlando, Florida.
(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO